Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY, Bérard E, Bréal C, Dulucq S, Réa D, Nicolini F, Forcade E, Dufossée M, Pasquet JM, Turcq B, Bidet A, Milpied N, Déchanet-Merville J, Lafarge X, Etienne G, Mahon FX; French Intergroup in Chronic Myeloid Leukemia. Dumas PY, et al. Among authors: pasquet jm. Cancer Med. 2019 Sep;8(11):4976-4985. doi: 10.1002/cam4.2371. Epub 2019 Jul 9. Cancer Med. 2019. PMID: 31287239 Free PMC article.
Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto JP, Raynaud S, Tartare-Deckert S, Auberger P. Fenouille N, et al. Among authors: pasquet jm. Cancer Res. 2010 Dec 1;70(23):9659-70. doi: 10.1158/0008-5472.CAN-10-2034. Epub 2010 Nov 23. Cancer Res. 2010. PMID: 21098700
MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms.
Dumas PY, Mansier O, Prouzet-Mauleon V, Koya J, Villacreces A, Brunet de la Grange P, Luque Paz D, Bidet A, Pasquet JM, Praloran V, Salin F, Kurokawa M, Mahon FX, Cardinaud B, Lippert E. Dumas PY, et al. Among authors: pasquet jm. BMC Cancer. 2018 Nov 12;18(1):1098. doi: 10.1186/s12885-018-4993-2. BMC Cancer. 2018. PMID: 30419846 Free PMC article.
Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL.
Dumas PY, Naudin C, Martin-Lannerée S, Izac B, Casetti L, Mansier O, Rousseau B, Artus A, Dufossée M, Giese A, Dubus P, Pigneux A, Praloran V, Bidet A, Villacreces A, Guitart A, Milpied N, Kosmider O, Vigon I, Desplat V, Dusanter-Fourt I, Pasquet JM. Dumas PY, et al. Among authors: pasquet jm. Haematologica. 2019 Oct;104(10):2017-2027. doi: 10.3324/haematol.2018.205385. Epub 2019 Mar 28. Haematologica. 2019. PMID: 30923103 Free PMC article. Clinical Trial.
Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Fernandez S, Desplat V, Villacreces A, Guitart AV, Milpied N, Pigneux A, Vigon I, Pasquet JM, Dumas PY. Fernandez S, et al. Among authors: pasquet jm. Int J Mol Sci. 2019 Jul 12;20(14):3429. doi: 10.3390/ijms20143429. Int J Mol Sci. 2019. PMID: 31336846 Free PMC article. Review.
Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia.
Dumas PY, Villacreces A, Guitart AV, El-Habhab A, Massara L, Mansier O, Bidet A, Martineau D, Fernandez S, Leguay T, Pigneux A, Vigon I, Pasquet JM, Desplat V. Dumas PY, et al. Among authors: pasquet jm. Clin Cancer Res. 2021 Nov 1;27(21):6012-6025. doi: 10.1158/1078-0432.CCR-20-3114. Epub 2021 Aug 16. Clin Cancer Res. 2021. PMID: 34400415
69 results